Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

p53 status identifies triple-negative breast cancer patients who do not respond to adjuvant chemotherapy.

Breast (Edinburgh, Scotland) - 1 Jun 2015

Coradini Danila, Biganzoli Elia, Ardoino Ilaria, Ambrogi Federico, Boracchi Patrizia, Demicheli Romano, Daidone Maria Grazia, Moliterni Angela

Abstract excerpt

Genomic analysis and protein expression assimilate triple-negative breast cancers (TNBC) with basal-like breast tumors. TNBCs, however, have proved to encompass also tumors with normal-like phenotype and known to have favorable prognosis and to respond to chemotherapy. In a recent paper, we have provided evidence that p53 status is able to subdivide TNBCs into two distinct subgroups with different outcome, and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Chemotherapy, Adjuvant
Share to Cyclophosphamide

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Doxorubicin

Share to Fluorouracil

Share to Mastectomy

Share to Methotrexate

Share to Topoisomerase II Inhibitors

Share to Triple Negative Breast Neoplasms

Source

Identifiers

PMID: 25698149
DOI: 10.1016/j.breast.2015.01.007

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

p53 status identifies triple-negative breast cancer patients who do not respond to adjuvant chemotherapy.PMID 25698149Read ↗

Differences in prognosis and efficacy of chemotherapy by p53 expression in triple-negative breast cancer.Semantic proximity Read ↗

p53 in breast cancer subtypes and new insights into response to chemotherapy.Semantic proximity Read ↗

Predictive and prognostic role of p53 according to tumor phenotype in breast cancer patients treated with preoperative chemotherapy: a single-institution analysis.Semantic proximity Read ↗

Comparative Analysis of Gene Correlation Networks of Breast Cancer Patients Based on Mutations in TP53.Semantic proximity Read ↗

Prognostic impact of clinicopathologic parameters in stage II/III breast cancer treated with neoadjuvant docetaxel and doxorubicin chemotherapy: paradoxical features of the triple negative breast cancer.Semantic proximity Read ↗

TP53 status for prediction of sensitivity to taxane versus non-taxane neoadjuvant chemotherapy in breast cancer (EORTC 10994/BIG 1-00): a randomised phase 3 trial.Semantic proximity Read ↗

A mutant TP53 gene status is associated with a poor prognosis and anthracycline-resistance in breast cancer patients.Semantic proximity Read ↗

TP53 status and response to chemotherapy in breast cancer.Semantic proximity Read ↗

TP53 status and response to treatment in breast cancers.Semantic proximity Read ↗

Association between Mutation and Expression of TP53 as a Potential Prognostic Marker of Triple-Negative Breast CancerSemantic proximity Read ↗

Treatment outcomes and clinicopathologic characteristics of triple-negative breast cancer patients who received platinum-containing chemotherapy.Semantic proximity Read ↗

Neo-adjuvant doxorubicin and cyclophosphamide followed by paclitaxel in triple-negative breast cancer among BRCA1 mutation carriers and non-carriers.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.